221 related articles for article (PubMed ID: 11219775)
1. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer.
Hoque A; Menter DG; Sahin AA; Sneige N; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):153-4. PubMed ID: 11219775
[No Abstract] [Full Text] [Related]
2. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ
J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365
[TBL] [Abstract][Full Text] [Related]
3. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden.
Wärnberg F; Bergh J; Zack M; Holmberg L
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):495-9. PubMed ID: 11352860
[TBL] [Abstract][Full Text] [Related]
5. [Differential atypical ductal hyperplasia/DCIS/invasive carcinoma diagnosis and significance of micrometastases].
Stosiek P
Zentralbl Chir; 1998; 123 Suppl 5():13. PubMed ID: 10063563
[TBL] [Abstract][Full Text] [Related]
6. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
Bofin AM; Lydersen S; Hagmar BM
Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
[TBL] [Abstract][Full Text] [Related]
7. A case of ductal carcinoma in situ of the breast.
Yoshida M; Kinoshita T
Jpn J Clin Oncol; 2009 Feb; 39(2):132. PubMed ID: 19155284
[No Abstract] [Full Text] [Related]
8. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ.
Rosen EL; Smith-Foley SA; DeMartini WB; Eby PR; Peacock S; Lehman CD
Breast J; 2007; 13(6):545-50. PubMed ID: 17983393
[TBL] [Abstract][Full Text] [Related]
9. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
Roger P; Sahla ME; Mäkelä S; Gustafsson JA; Baldet P; Rochefort H
Cancer Res; 2001 Mar; 61(6):2537-41. PubMed ID: 11289127
[TBL] [Abstract][Full Text] [Related]
10. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis and VEGF expression in pre-invasive lesions of the human breast.
Viacava P; Naccarato AG; Bocci G; Fanelli G; Aretini P; Lonobile A; Evangelista G; Montruccoli G; Bevilacqua G
J Pathol; 2004 Oct; 204(2):140-6. PubMed ID: 15376259
[TBL] [Abstract][Full Text] [Related]
12. [Ductal carcinoma in situ of the breast].
Rueda Domínguez A; Alonso Muñoz MC; Gómez Gómez A; Ojeda González B
Med Clin (Barc); 1993 Oct; 101(14):548-56. PubMed ID: 8231402
[No Abstract] [Full Text] [Related]
13. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
14. Correlation between type and grade of ductal carcinoma in situ and concomitant invasive ductal carcinoma of the breast.
Rudnicka L; Stachura J
Pol J Pathol; 2000; 51(3):137-43. PubMed ID: 11247396
[TBL] [Abstract][Full Text] [Related]
15. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study.
Collins LC; Tamimi RM; Baer HJ; Connolly JL; Colditz GA; Schnitt SJ
Cancer; 2005 May; 103(9):1778-84. PubMed ID: 15770688
[TBL] [Abstract][Full Text] [Related]
16. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ
Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453
[TBL] [Abstract][Full Text] [Related]
17. The prognostic relevance of estimates of proliferative activity in early breast cancer.
Heatley MK; Maxwell P; Whiteside C; Ewing P; Toner PG
Histopathology; 2005 Jan; 46(1):110-1. PubMed ID: 15656896
[No Abstract] [Full Text] [Related]
18. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness.
Costantini M; Belli P; Rinaldi P; Bufi E; Giardina G; Franceschini G; Petrone G; Bonomo L
Clin Radiol; 2010 Dec; 65(12):1005-12. PubMed ID: 21070905
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue.
Alò PL; Visca P; Botti C; Galati GM; Sebastiani V; Andreano T; Di Tondo U; Pizer ES
Am J Clin Pathol; 2001 Jul; 116(1):129-34. PubMed ID: 11447743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
